Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

1.720 +0.290 (+20.28%)
Official Closing Price Updated: 8:00 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 Next >
News headline image
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
News headline image
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
From CEL-SCI Corporation
Via Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
From CEL-SCI Corporation
Via Business Wire
News headline image
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.